Cost-effectiveness of reflex laboratory-based cryptococcal antigen screening for the prevention and treatment of cryptococcal meningitis in Botswana

Mark W Tenforde; Charles Muthoga; Andrew Callaghan; Ponego Ponatshego; Julia Ngidi; Madisa Mine; Alexander Jordan; Tom Chiller; Bruce A Larson; Joseph N Jarvis

doi:10.12688/wellcomeopenres.15464.2

Cost-effectiveness of reflex laboratory-based cryptococcal antigen screening for the prevention and treatment of cryptococcal meningitis in Botswana

Wellcome Open Res. 2020 Mar 13:4:144. doi: 10.12688/wellcomeopenres.15464.2. eCollection 2019.

Authors

Mark W Tenforde^{1

2}, Charles Muthoga^{3

4}, Andrew Callaghan³, Ponego Ponatshego⁴, Julia Ngidi^{4

5}, Madisa Mine⁵, Alexander Jordan⁶, Tom Chiller⁶, Bruce A Larson^#⁷, Joseph N Jarvis^#^{3

4

8}

Affiliations

¹ University of Washington School of Medicine, Seattle, Washington, 98195, USA.
² University of Washington School of Public Health, Seattle, WA, 98195, USA.
³ Botswana-UPenn Partnership, Gaborone, Botswana.
⁴ Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
⁵ National Health Laboratory, Gaborone, Botswana.
⁶ Centers for Disease Controls and Prevention, Atlanta, Georgia, 30329-4018, USA.
⁷ Boston University School of Public Health, Boston, MA, 02118, USA.
⁸ London School of Hygiene & Tropical Medicine, London, UK.

^# Contributed equally.

Abstract

Background: Cryptococcal antigen (CrAg) screening for antiretroviral therapy (ART)-naïve adults with advanced HIV/AIDS can reduce the incidence of cryptococcal meningitis (CM) and all-cause mortality. We modeled the cost-effectiveness of laboratory-based "reflex" CrAg screening for ART-naïve CrAg-positive patients with CD4<100 cells/µL (those currently targeted in guidelines) and ART-experienced CrAg-positive patients with CD4<100 cells/µL (who make up an increasingly large proportion of individuals with advanced HIV/AIDS). Methods: A decision analytic model was developed to evaluate CrAg screening and treatment based on local CD4 count and CrAg prevalence data, and realistic assumptions regarding programmatic implementation of the CrAg screening intervention. We modeled the number of CrAg tests performed, the number of CrAg positives stratified by prior ART experience, the proportion of patients started on pre-emptive antifungal treatment, and the number of incident CM cases and CM-related deaths. Screening and treatment costs were evaluated, and cost per death or disability-adjusted life year (DALY) averted estimated. Results: We estimated that of 650,000 samples undergoing CD4 testing annually in Botswana, 16,364 would have a CD4<100 cells/µL and receive a CrAg test, with 70% of patients ART-experienced at the time of screening. Under base model assumptions, CrAg screening and pre-emptive treatment restricted to ART-naïve patients with a CD4<100 cells/µL prevented 20% (39/196) of CM-related deaths in patients undergoing CD4 testing at a cost of US$2 per DALY averted. Expansion of preemptive treatment to include ART-experienced patients with a CD4<100 cells/µL resulted in 55 additional deaths averted (a total of 48% [94/196]) and was cost-saving compared to no screening. Findings were robust across a range of model assumptions. Conclusions: Reflex laboratory-based CrAg screening for patients with CD4<100 cells/µL is a cost-effective strategy in Botswana, even in the context of a relatively low proportion of advanced HIV/AIDS in the overall HIV-infected population, the majority of whom are ART-experienced.

Keywords: AIDS cost-effectiveness; CrAg; Cryptococcal antigen; HIV; modelling.

Abstract

Grants and funding